Bleeding is the most feared complication during extracorporeal membrane oxygenation (ECMO)
and is associated with high dosing of heparin. There is no consensus on antithrombin (AT)
supplementation during ECMO. However, AT is needed by heparin to properly anticoagulate. We
hypothesize that maintaining normal antithrombin levels during ECMO is associated with a less
heparin dosing and more adequate level of anticoagulation.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Policlinico Hospital
Collaborators:
Azienda Ospedaliera Città della Salute e della Scienza di Torino Azienda Ospedaliera San Gerardo di Monza The Mediterranean Institute for Transplantation and Advanced Specialized Therapies